Abilify Compulsive Gambling Side Effects National Class Action
QC Dec 12, 2016 [en]
Application for Authorization
CONSUMER LAW GROUP has launched a Canada-wide class action lawsuit against Bristol-Myers Squibb Canada, Otsuka Canada Pharmaceutical Inc., and Lundbeck Canada Inc., the makers of Abilify and Abilify Maintena, on behalf of individuals who developed compulsive behaviours such as gambling addiction after taking the drugs.
Abilify, the brand name of the medication aripiprazole, is prescribed to thousands of people in Canada to treat depression, bipolar disorder, schizophrenia and other mental health issues. However, this antipsychotic agent has been linked to pathological gambling, binge eating, uncontrollable shopping and hypersexual behaviour.
Several studies have shown an association between Abilify and compulsive gambling:
• In 2010, the journal Australian & New Zealand Journal of Psychology published the story of a woman with schizophrenia who took Abilify, gained nearly 20 pounds in six months through compulsive eating and gambled away thousands of dollars. She had no prior history of such behavior.
• In 2011, the British Journal of Psychiatry published a study that examined three patients who used Abilify and exhibited the disorder; all the patients stopped gambling after they stopped using the drug.
• In 2014, the medical journal JAMA Internal Medicine published a study that analyzed the records of 1,580 patients who had reported adverse drug effects involving compulsive gambling and other impulse behavior issues. The researchers conducting the study reported that they found a “significant” link between use of Abilify and gambling.
• In 2014, the medical journal Addictive Behaviors published a study that looked at 8 people who were being treated for compulsive gambling. A direct link between Abilify and the disorder was present in 7 of the patients. The researchers reported those patients could once again control their impulse to gamble after they were taken off of Abilify.
On November 19, 2012, the European Medicines Agency modified the product label to warn of the risk of pathological gambling, even where the patient had no prior history of gambling. On November 2, 2015, Health Canada ordered labelling changes to the prescription antipsychotic drugs Abilify and Abilify Maintena to advise of an increased risk of impulsive behaviours of pathological gambling and hypersexuality. On May 3, 2016, the U.S. Food and Drug Administration (FDA) announced that warnings regarding “compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex” would be added to the Abilify label.
The class action lawsuit identifies the group of affected persons as:
All persons residing in Canada who were prescribed and have ingested and/or injected the drug(s), ABILIFY® and/or ABILIFY MAINTENA® (aripiprazole) and their successors, assigns, family members, and dependants, or any other group to be determined by the Court.
If you or a member of your family have used the antipsychotic agents Abilify or Abilify Maintena and were subsequently diagnosed with pathological gambling, and you wish more information on potential compensation or to be kept advised of the status of the Abilify Compulsive Gambling Side Effects National Class Action litigation or any resulting compensation from the Abilify Compulsive Gambling Side Effects Lawsuit in Canada, Quebec or Ontario, please provide your contact information to our law firm using the below form.
IF YOU WISH TO JOIN THE CLASS ACTION OR TO SIMPLY GET MORE INFORMATION, PLEASE COMPLETE THE FORM BELOW. Please note that providing your information creates no financial obligation for you. You are not charged any fee or cost for joining this class action. Our law firm is paid a contingency fee from the compensation recovered, only if the class action is successful. All information contained in this transmission is confidential and Consumer Law Group agrees to protect this information against unauthorized use, publication or disclosure.